glp-1 drug companies Swiss Re says drugs could reduce US mortality by up to 6.4% This week in 5 numbers:

[DOI] [PubMed] [Google Scholar] 4.Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA

Some studies showed higher amounts of stomach contents, but aspiration events were rare and occurred at rates similar to those of patients not taking the medications

In smaller acute metabolic studies with DPP-4 inhibitors, a reduction of the post-prandial rise in triglycerides, and apolipoprotein-B 48 was observed

Some of this is driven by cost and access problems

Previous WHO recommendations focused on the latter

showed that obesity in patients with T1D is associated with an increased risk of chronic kidney disease (CKD) compared with T2D (23)